Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Change in Taxes (2017 - 2025)

Historic Change in Taxes for Protagonist Therapeutics (PTGX) over the last 8 years, with Q2 2025 value amounting to -$1.9 million.

  • Protagonist Therapeutics' Change in Taxes fell 17943.79% to -$1.9 million in Q2 2025 from the same period last year, while for Sep 2025 it was -$1.0 million, marking a year-over-year decrease of 19695.01%. This contributed to the annual value of $2.7 million for FY2024, which is N/A changed from last year.
  • According to the latest figures from Q2 2025, Protagonist Therapeutics' Change in Taxes is -$1.9 million, which was down 17943.79% from -$800000.0 recorded in Q1 2025.
  • Protagonist Therapeutics' Change in Taxes' 5-year high stood at $3.3 million during Q1 2024, with a 5-year trough of -$1.9 million in Q2 2025.
  • Moreover, its 4-year median value for Change in Taxes was $33000.0 (2022), whereas its average is $164363.6.
  • The largest annual percentage gain for Protagonist Therapeutics' Change in Taxes in the last 5 years was 260882.35% (2021), contrasted with its biggest fall of 1025000.0% (2021).
  • Over the past 4 years, Protagonist Therapeutics' Change in Taxes (Quarter) stood at $921000.0 in 2021, then crashed by 96.42% to $33000.0 in 2022, then surged by 4869.7% to $1.6 million in 2024, then crashed by 215.18% to -$1.9 million in 2025.
  • Its Change in Taxes was -$1.9 million in Q2 2025, compared to -$800000.0 in Q1 2025 and $1.6 million in Q4 2024.